Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 15, 2019. The report details the vesting of Deferred Bonus Awards and Matching Awards granted in 2016 under the 2009 Deferred Annual Bonus Plan (DABP). The three-year performance period for these awards concluded on December 31, 2018.
Key Financial Metrics and Performance Outcomes
The filing focuses on executive compensation metrics rather than corporate financial statements. Key performance outcomes for the 2016 awards are as follows:
- Adjusted Free Cash Flow (AFCF): The company achieved £13.18 billion against a revised threshold of £11.57 billion (increased by £0.22 billion). This resulted in a 77% vesting level for this portion of the award.
- Total Shareholder Return (TSR): GSK ranked 6th out of 10 comparator companies. This fell below the threshold vesting level, resulting in 0% vesting for this portion.
- R&D New Products: New Product sales reached £10.435 billion, exceeding the maximum vesting level of £8.532 billion. This resulted in 100% vesting for this portion.
- Overall Vesting: The total vesting for the 2016 award was 41%, with 59% of the awards lapsing.
The filing does not provide corporate-level revenue, profit, cash flow, debt, or liquidity figures for the reporting period.
Material Changes and Adjustments
The Remuneration Committee adjusted the AFCF target and vesting scale for the 2016 DABP Matching Awards. This adjustment was made to reduce the level of outperformance attributable to the original timing assumption regarding the Loss of Advair Exclusivity. Additionally, the filing notes that the Remuneration Committee reviewed and agreed to adjust the AFCF target for the 2017 DABP matching awards, with full details to be provided in the Remuneration Report.
Management Commentary and Transaction Details
On February 14, 2019, conditional awards vested for several Persons Discharging Managerial Responsibilities (PDMRs). The closing share prices at the point of vesting were £15.66 for an Ordinary Share and $40.86 for an American Depositary Share (ADS). The following transactions were reported:
| Name | Position | Deferred Shares | Matching Shares | Total Shares |
|---|---|---|---|---|
| Ms E Walmsley | Chief Executive Officer | 32,596 | 19,234 | 51,830 |
| Mr R Connor | President, Global Vaccines | 11,073 | 6,534 | 17,607 |
| Mr S Dingemans | Chief Financial Officer | 43,044 | 25,398 | 68,442 |
| Mr N Hirons | SVP, Global Ethics and Compliance | 15,914 | 9,392 | 25,306 |
| Mr D Redfern | Chief Strategy Officer | 20,254 | 11,952 | 32,206 |
| Mr P Thomson | President, Global Affairs | 9,064 | 5,349 | 14,413 |
| Ms C Thomas | SVP, Human Resources | 29,636 | 17,488 | 47,124 |
All transactions were conducted on the London Stock Exchange (XLON) at a price of £0.00, as these were vesting events rather than market purchases.
Investor Verification Checklist
- Verify the impact of the AFCF target adjustment on future executive compensation costs.
- Confirm the specific details of the 2017 DABP matching award adjustments in the upcoming Remuneration Report.
- Review the full Remuneration Report to understand the methodology for the "Loss of Advair Exclusivity" timing assumption.
- Check subsequent filings for the actual financial performance of the company for the fiscal year ending December 31, 2018, as this filing only contains compensation metrics.